Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-03 4:34 pm Purchase | 13G | Cidara Therapeutics, Inc. CDTX | TCG Crossover GP II LLC | 1,005,901 9.200% | 1,005,901 (New Position) | Filing History |
| 2024-11-22 4:41 pm Purchase | 13G | Dianthus Therapeutics, Inc. DNTH | TCG Crossover GP II LLC | 1,501,624 5.100% | 1,501,624 (New Position) | Filing History |
| 2024-11-20 4:24 pm Purchase | 13G | Tango Therapeutics, Inc. TNGX | TCG Crossover GP II LLC | 10,500,612 9.800% | 10,500,612 (New Position) | Filing History |
| 2024-11-13 4:27 pm Sale | 13G | Mineralys Therapeutics, Inc. MLYS | TCG Crossover GP II LLC | 2,470,265 5.000% | -714,920 (-22.45%) | Filing History |
| 2024-11-13 4:21 pm Sale | 13G | Astria Therapeutics, Inc. ATXS | TCG Crossover GP II LLC | 2,761,861 4.900% | -1,607,067 (-36.78%) | Filing History |
| 2024-11-07 4:27 pm Purchase | 13G | EyePoint Pharmaceuticals, Inc. EYPT | TCG Crossover GP II LLC | 3,572,335 5.200% | 3,572,335 (New Position) | Filing History |
| 2024-09-27 4:52 pm Purchase | 13G | Third Harmonic Bio, Inc. THRD | TCG Crossover GP II LLC | 2,415,000 5.900% | 2,415,000 (New Position) | Filing History |
| 2024-09-20 4:21 pm Purchase | 13G | Fulcrum Therapeutics, Inc. FULC | TCG Crossover GP II LLC | 5,000,000 9.400% | 5,000,000 (New Position) | Filing History |
| 2024-08-26 6:49 pm Purchase | 13G | Amylyx Pharmaceuticals, Inc. AMLX | TCG Crossover GP II LLC | 4,643,812 6.800% | 4,643,812 (New Position) | Filing History |
| 2024-03-15 4:18 pm Purchase | 13G | Nektar Therapeutics NKTR | TCG Crossover GP II LLC | 20,046,350 9.900% | 20,046,350 (New Position) | Filing History |
| 2024-02-15 4:20 pm Purchase | 13G | Mineralys Therapeutics, Inc. MLYS | TCG Crossover GP II LLC | 3,185,185 6.400% | 3,185,185 (New Position) | Filing History |
| 2024-02-15 4:17 pm Purchase | 13G | Adverum Biotechnologies, Inc. ADVM | TCG Crossover GP II LLC | 2,076,357 9.900% | 2,076,357 (New Position) | Filing History |
| 2024-01-16 4:18 pm Purchase | 13G | Astria Therapeutics, Inc. ATXS | TCG Crossover GP II LLC | 4,368,928 9.900% | 4,368,928 (New Position) | Filing History |
| 2023-10-16 4:37 pm Purchase | 13G | VistaGen Therapeutics, Inc. VTGN | TCG Crossover GP II LLC | 2,702,157 9.900% | 2,702,157 (New Position) | Filing History |